459 related articles for article (PubMed ID: 16452496)
21. Ultrastructural study on nephrin expression in experimental puromycin aminonucleoside nephrosis.
Lee YK; Kwon T; Kim DJ; Huh W; Kim YG; Oh HY; Kawachi H
Nephrol Dial Transplant; 2004 Dec; 19(12):2981-6. PubMed ID: 15385636
[TBL] [Abstract][Full Text] [Related]
22. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
[TBL] [Abstract][Full Text] [Related]
23. Fluvastatin attenuated the effect of expression of β1 integrin in PAN-treated podocytes by inhibiting reactive oxygen species.
Liu J; Zhang B; Chai Y; Xu Y; Xing C; Wang X
Mol Cell Biochem; 2015 Jan; 398(1-2):207-15. PubMed ID: 25240415
[TBL] [Abstract][Full Text] [Related]
24. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome.
Aizawa K; Takeda S; Tashiro Y; Yorozu K; Hirata M; Kanada H; Moriguchi Y; Endo K
Am J Nephrol; 2012; 36(5):419-26. PubMed ID: 23128049
[TBL] [Abstract][Full Text] [Related]
25. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of nestin protects podocytes from apoptosis induced by puromycin aminonucleoside.
Wen D; You L; Zhang Q; Zhang L; Gu Y; Hao CM; Chen J
Am J Nephrol; 2011; 34(5):423-34. PubMed ID: 21952051
[TBL] [Abstract][Full Text] [Related]
27. Novel expression of sodium/myo-inositol co-transporter in podocytes in puromycin aminonucleoside nephrosis.
Watanabe Y; Kobayashi T; Yaoita E; Kawachi H; Yamauchi A; Inoue T; Shimizu F; Yoshida Y; El-Shemi AG; Okada H; Suzuki H; Yamamoto T
Nephrol Dial Transplant; 2004 Apr; 19(4):817-22. PubMed ID: 15031335
[TBL] [Abstract][Full Text] [Related]
28. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
Toyonaga J; Tsuruya K; Ikeda H; Noguchi H; Yotsueda H; Fujisaki K; Hirakawa M; Taniguchi M; Masutani K; Iida M
Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effects of orosomucoid on the glomerular barrier in puromycin aminonucleoside-induced nephrosis.
Hjalmarsson C; Lidell ME; Haraldsson B
Nephrol Dial Transplant; 2006 May; 21(5):1223-30. PubMed ID: 16410268
[TBL] [Abstract][Full Text] [Related]
30. The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis.
Takeuchi S; Hiromura K; Tomioka M; Takahashi S; Sakairi T; Maeshima A; Kaneko Y; Kuroiwa T; Nojima Y
Nephron Exp Nephrol; 2010; 116(1):e3-10. PubMed ID: 20502051
[TBL] [Abstract][Full Text] [Related]
31. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Fukuda A; Fujimoto S; Iwatsubo S; Kawachi H; Kitamura K
Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
[TBL] [Abstract][Full Text] [Related]
32. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
[TBL] [Abstract][Full Text] [Related]
33. [Differential expressions of miRNAs in kidney in puromycin aminonucleoside nephropathy model and intervened effects of Leizhi capsule].
Sun W; Li CQ; Chen JH; Shao JD; Zhou D; Zhang L; Gao K
Zhongguo Zhong Yao Za Zhi; 2013 Jan; 38(1):81-90. PubMed ID: 23596882
[TBL] [Abstract][Full Text] [Related]
34. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
[TBL] [Abstract][Full Text] [Related]
35. [Relationship between podocyte molecule's distribution and expression, foot process morphology and proteinuria].
Guan N; Deng JH; Ding J; Zhang JJ; Yang JY
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):139-44. PubMed ID: 15100730
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of olfactomedin-1 and myocilin in podocytes during puromycin aminonucleoside nephrosis.
Bohr DC; Koch M; Kritzenberger M; Fuchshofer R; Tamm ER
Nephrol Dial Transplant; 2011 Jan; 26(1):83-92. PubMed ID: 20595200
[TBL] [Abstract][Full Text] [Related]
37. Protein tyrosine phosphatase 1B inhibition protects against podocyte injury and proteinuria.
Kumagai T; Baldwin C; Aoudjit L; Nezvitsky L; Robins R; Jiang R; Takano T
Am J Pathol; 2014 Aug; 184(8):2211-24. PubMed ID: 24951831
[TBL] [Abstract][Full Text] [Related]
38. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.
Shen X; Jiang H; Ying M; Xie Z; Li X; Wang H; Zhao J; Lin C; Wang Y; Feng S; Shen J; Weng C; Lin W; Wang H; Zhou Q; Bi Y; Li M; Wang L; Zhu T; Huang X; Lan HY; Zhou J; Chen J
Sci Rep; 2016 Sep; 6():32087. PubMed ID: 27580845
[TBL] [Abstract][Full Text] [Related]
39. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria.
Lahdenkari AT; Lounatmaa K; Patrakka J; Holmberg C; Wartiovaara J; Kestilä M; Koskimies O; Jalanko H
J Am Soc Nephrol; 2004 Oct; 15(10):2611-8. PubMed ID: 15466265
[TBL] [Abstract][Full Text] [Related]
40. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression.
Eto N; Wada T; Inagi R; Takano H; Shimizu A; Kato H; Kurihara H; Kawachi H; Shankland SJ; Fujita T; Nangaku M
Kidney Int; 2007 Aug; 72(4):455-63. PubMed ID: 17457371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
